盐酸埃克替尼治疗50例晚期肺腺癌的临床观察  

Efficacy and safety of icotinib hydrochloride in the treatment of 50 patients with advanced adenocarcinoma of lung

作　　者：张洁[1] 鲁晓宁[1] 班丽英[1] 

机构地区：[1]大连医科大学附属第一医院,大连116011

出　　处：《中国新药杂志》2013年第9期1068-1071,共4页Chinese Journal of New Drugs

摘　　要：目的:观察埃克替尼对晚期肺腺癌的临床疗效及不良反应及其对生活质量的影响。方法:回顾研究2011年9月-2012年8月间ⅢB～Ⅳ期肺腺癌患者50例,口服埃克替尼125 mg,bid,直至病情进展或出现不能耐受的不良反应。结果:50例可评价肺腺癌患者中,完全缓解(CR)0例,部分缓解(PR)22例(44%),疾病稳定(SD)19例(38%),疾病进展(PD)9例(18%),总有效率(RR)为44%,总疾病控制率(DCR)为82%,总的症状缓解率为80%。吸烟与不吸烟、男性与女性未显示出统计学差异,但一线选择靶向治疗与二线选择靶向治疗组疗效有统计学差异(组间P<0.05)。用药后有33例(66%)患者出现不良反应,其中最常见的是皮疹(14例,28%),腹泻8例(16%),皮肤瘙痒5例(10%),胃脘烧灼感4例(8%),肝功能轻度损害2例(4%)。结论:埃克替尼治疗晚期肺腺癌疗效好,可以显著改善肺腺癌患者的临床症状及生存质量,毒副反应较小、安全、易耐受。Objective： To observe the efficacy, effect on the quality of life and toxic reactions of icotinib hydrochloride in the treatment of patients with advanced adenocarcinoma of lung. Methods： Fifty patients with IIIB to IV adenocarcinoma of lung were retrospectively analyzed from September 2011 to August 2012. Icotinib hydrochloride （125 mg, three times a day） was orally taken until the disease progressed or intolerable toxic reactions occurred. Results： All 50 patients were evaluable for efficacy. Among the 50 patients, there was none with complete response （CR）, 22 patients with partial response （PR, 44% ）, 19 with stable disease （SD, 38% ） and 9 with progression （PD, 18% ）. The total response rate （RR） was 44%, the disease control rate （DCR） was 82% , and the rate of symptomatic relief was 80%. No statistically significant differences were found in the response rates between smokers and nonsmokers and between males and females. However, significant differences were found in the response rate between patients with and without previous chemotherapy （P 〈 0.05）. Toxic reactions occurred in 33 patients （66%）. The main toxic reactions of icotinib were skin rash （14 patients, 28% ）, diarrhoea （8 patients, 16% ） , itch of skin （5 patients, 10% ） and heartburn （4 patients, 8% ） , and the occasional reaction was mild liv- er damage （2 patients, 4% ）. Conclusion： Icotinib obviously improves clinical symptoms and the quality of life of the patients with advanced adenoearcinoma of lung; it is effective, safe and well-tolerated.

关 键 词：肺腺癌 盐酸埃克替尼 分子靶向治疗 表皮生长因子受体 常见不良反应事件评价标准 

分 类 号：R979.1[医药卫生—药品]